Test Price
2,800 AEDโ Home Collection Available
CDH15 Gene Mental Retardation, Autosomal Dominant Type 3 (MRD3) Genetic Test in UAE | 2,800 AED
Executive Summary & Core Metrics
Next-Generation Sequencing (NGS) analysis of the CDH15 gene for autosomal dominant intellectual disability type 3 (MRD3) with 99.9% diagnostic sensitivity via ISO-accredited processing.
- Accuracy Guarantee: 99.9% variant detection with confirmatory Sanger validation.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Telephonic post-test consultation for result interpretation and family counseling.
- Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This advanced Next-Generation Sequencing (NGS) test analyzes the CDH15 gene for pathogenic variants associated with autosomal dominant intellectual disability type 3 (MRD3), delivering a precise molecular diagnosis for patients with neurodevelopmental delay. The complete coding region and splice-site boundaries are interrogated using high-depth NGS, with all clinically significant variants confirmed via bidirectional Sanger sequencing to ensure diagnostic certainty.
| Feature | DNA Labs UAE CDH15 NGS Test | Closest Alternative (Single-Gene Sanger) |
|---|---|---|
| Precision | 99.9% variant detection with Sanger validation | ~95% for targeted region |
| Method | NGS + confirmatory Sanger sequencing | Sanger sequencing only |
| Turnaround Time | 3 โ 4 weeks | 6 โ 8 weeks |
Physician Insight & Safety Protocols
โGenetic testing for MRD3 provides families with a definitive molecular answer that can guide early intervention, educational planning, and recurrence-risk counseling. However, a positive finding must always be interpreted within the full clinical context, including detailed family history and developmental assessments. Patients and caregivers should discuss all results with a qualified genetics specialist before making any management decisions.โ
โ Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
โ ๏ธ Medication Advisory
Genetic test results complement, but never replace, ongoing clinical management. Continue all prescribed therapies and consult your physician before modifying any treatment plan.
๐ฉบ Safety Exclusion Criteria & Red Flags
- Severe coagulopathy or active bleeding disorder contraindicating venipuncture.
- Uncontrollable seizures or acute neuroregression requiring emergency care.
- ER Red Flags: Sudden loss of consciousness, new-onset weakness, status epilepticus โ seek immediate medical attention before proceeding with testing.
- Inability to provide a viable blood or DNA sample (alternative collection may be arranged).
Patient FAQ & Clinical Guidance
1. What does the CDH15 gene test detect?
This NGS test identifies pathogenic mutations in the CDH15 gene responsible for autosomal dominant intellectual disability type 3 (MRD3). The analysis screens the entire coding region and splice junctions, providing a definitive yes/no result for clinically significant alterations that cause neurodevelopmental delay. A positive outcome enables tailored educational, therapeutic, and surveillance planning along with accurate recurrence-risk counseling for family members.
2. How is the sample collected and when will I receive results?
A licensed mobile phlebotomist collects a peripheral whole blood sample at your home between 8 AM and 11 PM. The specimen is transported via temperature-controlled cold chain to our ISO-accredited laboratory. Results are issued within 3 to 4 weeks from sample receipt, accompanied by a detailed clinical report and telephonic guidance from our genetics team.
3. Who should consider this genetic test?
This test is indicated for children and adults presenting with unexplained intellectual disability, global developmental delay, or a family history consistent with autosomal dominant inheritance. A clinical genetics evaluation should precede testing to confirm appropriateness. Prenatal and preimplantation genetic testing applications require separate specialist consultation.
4. Does insurance cover the cost of this test?
Coverage varies by insurer and policy. Our team can verify direct billing eligibility via WhatsApp +971 54 548 8731. Submit a pre-authorization request along with your physician referral and clinical notes to determine out-of-pocket costs before booking.
UAE Regulatory & Data Privacy Adherence
Compliance Framework:
- Patient data handled in accordance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Clinical safety and informed consent procedures follow Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Laboratory operations ISO 9001:2015 certified under certificate reference INT/EGQ/2509DA/3139.
- All genetic results are released only after verified consent and in compliance with UAE genetic testing regulations governing minors and vulnerable populations.
Clinical & Logistical Metadata
| Test Name | CDH15 Gene (MRD3) NGS Test โ Autosomal Dominant Intellectual Disability Type 3 |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 โ 4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (preferred) or DNA on FTA Card โ VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (available daily 8 AM โ 11 PM) |
| Methodology Used | Next-Generation Sequencing (NGS) with confirmatory Sanger validation |
| ICD-10-CM Code | F78, Q99.8 |
| LOINC Code | 104200-5 |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE Corporate Lab Branding: DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians